scholarly journals Obesity-Related Chronic Kidney Disease—The Role of Lipid Metabolism

Metabolites ◽  
2015 ◽  
Vol 5 (4) ◽  
pp. 720-732 ◽  
Author(s):  
Peter Mount ◽  
Matthew Davies ◽  
Suet-Wan Choy ◽  
Natasha Cook ◽  
David Power
Keyword(s):  
Chronic Kidney Disease ◽  
Lipid Metabolism ◽  
Kidney Disease

Lipid Metabolism in Chronic Kidney Disease: The Role of Statins in Cardiovascular Risk

2007 ◽  
Vol 17 (1) ◽  
pp. 75-78 ◽  
Author(s):  
Christoph Wanner ◽  
Christiane Drechsler ◽  
Vera Krane
Keyword(s):  
Chronic Kidney Disease ◽  
Cardiovascular Risk ◽  
Lipid Metabolism ◽  
Kidney Disease

scholarly journals Recent Progress on Lipid Intake and Chronic Kidney Disease

2020 ◽  
Vol 2020 ◽  
pp. 1-11 ◽  
Author(s):  
Ke Pei ◽  
Ting Gui ◽  
Chao Li ◽  
Qian Zhang ◽  
Huichao Feng ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Lipid Metabolism ◽  
Kidney Disease ◽  
Recent Progress ◽  
Lipid Uptake ◽  
Vicious Cycle ◽  
Therapeutic Approaches ◽  
Lipid Abnormalities ◽  
Novel Therapeutic

The incidence of chronic kidney disease (CKD) is associated with major abnormalities in circulating lipoproteins and renal lipid metabolism. This article elaborates on the mechanisms of CKD and lipid uptake abnormalities. The viewpoint we supported is that lipid abnormalities directly cause CKD, resulting in forming a vicious cycle. On the theoretical and experiment fronts, this inference has been verified by elaborately elucidating the role of lipid intake and accumulation as well as their influences on CKD. Taken together, these findings suggest that further understanding of lipid metabolism in CKD may lead to novel therapeutic approaches.

scholarly journals EXPERT CONSENSUS. ROLE OF COMBINATION LIPID-LOWERING THERAPY (SIMVASTATIN/EZETIMIBE 20/10 MG) IN THE CORRECTION OF LIPID METABOLISM DISTURBANCES IN PATIENTS WITH CHRONIC KIDNEY DISEASE

2013 ◽  
Vol 12 (4) ◽  
pp. 75-78
Author(s):  
A. Catapano ◽  
E. V. Shlyakhto ◽  
A. I. Martynov ◽  
R. G. Oganov ◽  
V. V. Kukharchuk ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Lipid Metabolism ◽  
Kidney Disease ◽  
Expert Consensus ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy

Expert Consensus. Role of combination lipid-lowering therapy (simvastatin/ezetimibe 20/10 mg) in the correction of lipid metabolism disturbances in patients with chronic kidney disease.

scholarly journals Dyslipidemia as a pathogenetic factor of the progression of the chronic kidney disease

2019 ◽  
Vol 23 (5) ◽  
pp. 56-64
Author(s):  
E. N. Lebedeva ◽  
A. A. Vyalkova ◽  
S. N. Afonina ◽  
S. A. Chesnokova
Keyword(s):  
Chronic Kidney Disease ◽  
Lipid Metabolism ◽  
Kidney Disease ◽  
Functional State ◽  
Pathogenetic Role ◽  
Lipid Metabolism Disorders ◽  
Pathogenetic Factor ◽  
Lipids And Lipoproteins ◽  
Expression And Activity

The article presents current information on the pathogenetic role of lipid metabolism disorders and the value of lipotoxicity in renal pathology, contributing to the progression of nephropathy. The detected increase in cholesterol level, TAG, LDL, decrease in plasma HDL concentration in chronic kidney disease (CKD) is accompanied by significant changes in the composition of various lipoproteins caused by changes in the expression and activity of key proteins and enzymes involved in the biosynthesis, transport, remodeling and catabolism of lipids and lipoproteins. It has been proven that dyslipidemia in CKD affects the morphological and functional state of the kidneys, contributing to the development of renal lipotoxicity processes, affecting the structural and functional state of the kidneys, initiating oxidative stress, systemic inflammation, vascular damage, and dysregulation. To date, research on the significance of dyslipidemia as a pathogenetic factor in the formation of chronic kidney disease remains insufficiently studied. Dysregulation of lipid metabolism, leading to dyslipidemia, is often an undervalued complication of CKD.

Potential effect of pharmaceutical care to improve outcomes in patients with chronic kidney disease-mineral bone disorder in Sulaimani dialysis centers

2020 ◽  
pp. 82-94
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Pharmaceutical Care ◽  
Biochemical Parameters ◽  
Positive Impact ◽  
Potential Effect ◽  
Care Group ◽  
Mineral Bone Disorder ◽  
Bone Disorder

Objective: the present study was aimed to evaluate the role of pharmaceutical services in improving the outcome of mineral bone disorder in patients with advanced chronic kidney disease. Methodology: One hundred and twenty patients with chronic kidney disease-mineral bone disorder (CKD-MBD) screened for eligibility, seventy-six patients enrolled in the study and randomly allocated into two groups: pharmaceutical care and usual care, both groups interviewed by the pharmacist using specific questionnaire for assessing the quality of life (QoL). All the drug related problems (DRPs) including drug-drug interactions (DDIs) were recorded by the pharmacist. Blood samples were collected and utilized for analyzing the levels of vitamin D, phosphorous, calcium, albumin and parathyroid hormone at baseline and three months after. The pharmaceutical care group received all the educations about their medications and how to minimize DRPs; improve the QoL. Additionally, the pharmaceutical intervention included correcting the biochemical parameters. Results: Pharmaceutical care significantly improved patients QoL and minimized DRPs and DDIs. It was also effective in improving the biochemical parameters. Conclusion: Pharmaceutical care has a positive impact on improving the outcome of patients with CKD-MBD through attenuating DRPs, improving the biochemical parameters and the QoL.

Sign in / Sign up

Export Citation Format

Share Document